ClearPoint Neuro (US.CLPT)
资本配置审计 · 期间： 2010 – 2026
核心指标
US.CLPT · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 105.7% | → |
| ROE | -193.8% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 5.93 | ↓ |
| Gross Margin | 62.9% | → |
US.CLPT (ClearPoint Neuro) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ----------------------------- FCF Conversion 105.7% → ROE -193.8% ↓ Cash Conversion - → D/E Ratio 5.93 ↓ Gross Margin 62.9% →
核心指标
US.CLPT (ClearPoint Neuro) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY-----------------------------FCF Conversion 105.7% →ROE -193.8% ↓Cash Conversion - →D/E Ratio 5.93 ↓Gross Margin 62.9% →免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies